High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY191704, a human type 1 5 alpha-reductase inhibitor, in plasma.
A stereoselective reversed-phase liquid chromatographic method for the determination of compounds LY300502 and LY300503 (enantiomers of LY191704) in rat and dog plasma was developed. The assay involved extraction of the compounds using a strong cation-exchange solid-phase extraction column, from which the compounds are eluted with 1% of 1 M HCI in methanol. The enantiomers were separated on a Daicel Chiralcel OD-R column. The mobile phase consisted of water-acetonitrile-methanol (50:40:10, v/v) at a flow-rate of 0.3 ml/min. UV detection was achieved at 220 nm. The disposition of the enantiomers of LY191704 in rats and dogs was found to be stereoselective and species specific.
Farid
N A
NA
Division of Drug Metabolism and Disposition, Lilly Research Laboratories, Lilly Corporate Center, Indianpolis, IN 46285, USA.
Coleman
N L
NL
D058891:5-alpha Reductase Inhibitors; D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004285:Dogs; D004791:Enzyme Inhibitors / Q000097:blood*; D006801:Humans; D011786:Quality Control; D015363:Quinolones / Q000097:blood*; D051381:Rats; D012680:Sensitivity and Specificity; D013045:Species Specificity; D013237:Stereoisomerism
D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D015363:Quinolones; C081531:8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-3(2H)-one